Vimarsana
Biggest News Aggregation in the World

Page 21 - Global Head News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Global Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Global Head Today - Breaking & Trending Today

Sanofi: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma - Vimarsana News

Sanofi: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase

Novartis: presented results for kidney disease - Vimarsana News

Novartis: presented results for kidney disease

Novartis has presented the results of a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A receptor antagonist, in patients with...

Resorts World Cruises Becomes First Asian Cruise Line to Deploy Integrated MEOLEO Service from SES - Vimarsana News

Resorts World Cruises Becomes First Asian Cruise Line to Deploy Integrated MEOLEO Service from SES

Resorts World Cruises an international cruise line that is homegrown in Asia offering luxury and dynamic lifestyle experiences has announced an agreement with SES to install its fullyintegrated Medium Earth Orbit MEO and Low Earth Orbit LEO service on the cruise lines flagship Genting Dream with similar future plans for the Resorts World One cruise ship.

Safety & Security Manager - Israel/Palestine - Israel - Vimarsana News

Safety & Security Manager - Israel/Palestine - Israel

Program/Project Management Job in Israel about Safety and Security, requiring 5-9 years of experience, from Malteser; closing on 14 Jun 2024

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous nonsmall cell lung cancer in TROPIONLung01 Phase III trial - Vimarsana News

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous nonsmall cell lung cancer in TROPIONLung01 Phase III trial

Highlevel overall survival OS results from the TROPIONLung01 Phase III trial which previously met the dual primary endpoint of progressionfree survival PFS numerically favoured datopotamab deruxtecan DatoDXd compared to docetaxel in the overall trial population of patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC treated with at least one prior line of therapy.